Organon & Co. (OGN) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $8.70. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of OGN = $55.81 (+541.5% from the current price, the stock appears undervalued). Analyst consensus target is OGN = $7 (-25.3% upside).
Valuation: OGN trades at a trailing Price-to-Earnings (P/E) of 8.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.14.
Financials: revenue is $6.2B, +0.3%/yr average growth. Net income is $187M, growing at -27.4%/yr. Net profit margin is 3% (thin). Gross margin is 54.1% (-8.7 pp trend).
Balance sheet: total debt is $8.8B against $752M equity (Debt-to-Equity (D/E) ratio 11.7, leveraged). Current ratio is 1.82 (strong liquidity). Debt-to-assets is 68.4%. Total assets: $12.9B.
Analyst outlook: 3 / 8 analysts rate OGN as buy (38%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 30/100 (Fail), Past 100/100 (Pass), Health 33/100 (Fail), Moat 59/100 (Partial), Future 16/100 (Fail), Income 30/100 (Fail).
